BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Week in Review: Cardinal Health, Inc. (CAH) Uses M&A to Add Drug Distribution Reach in China


2/11/2013 10:52:48 AM

by Richard Daverman, PhD

February 9, 2013 -- Cardinal Health, a US drug distributor, spent $120 million to acquire six China drug distributors during the last year, paying less than $30 million for each one; 3SBio of Shenyang will be taken private by Dr. Jing Lou, its Chairman and CEO, along with a CITIC Private Equity company; Neusoft, a China software company, will buy out Phillips, its medical imaging JV partner; Zheijang Hisun Pharma will not purchase China rights for Celsion’s cancer drug, which failed its Phase III trial; Grandhope Biotech of Guangzhou in-licensed China rights to an autologous stem cell tendon-repair technology from Orthocell of Australia; CVie Therapeutics, a Lee's Pharma (HK: 00950) subsidiary, bought China rights to a Dyax treatment for hereditary angioedema; Janssen Pharma, a division of Johnson & Johnson, officially opened its China R&D Center in Shanghai Fenglin Life Science Park; and Solasia of Japan received SFDA permission to begin China trials of its anti-nausea patch product. More details….

Stock Symbols: (NYSE: CAH) (NSDQ: SSRX) (SHA: 600718) (SHA: 600267) (NSDQ: CLSN) (SHE: 300238) (NSDQ: DYAX) (NYSE: JNJ)



Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES